Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 30 jan 2026
- Citações
- 7
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
Frank A Sinicrope, Diana Segovia, Nalin Sharma, Steven R Alberts, Aaron Hardin, Thereasa Rich, Qian Shi
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Colonic Neoplasms
- Circulating Tumor DNA
- Leucovorin
- Female
- Fluorouracil
- Humans
- Male
- Middle Aged
- Neoplasm Staging
Veja também
Estudos relacionados
- Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12)
- Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
- Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial